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Abstract
Chronic cold agglutinin disease (CAD) is as ubgroup of autoimmune hemolytic anemia. PrimaryC AD has traditionally been
deﬁned by the absence of anyu nderlying or associated disease. The results of therapy with corticosteroids, alkylating agents
and interferon-a haveb een poor. Cold reactive immunoglobulins against erythrocyte surface antigens are essential to
pathogenesis of CAD.T hese cold agglutinins are monoclonal, usually IgMk autoantibodies with heavyc hain variable regions
encoded by the V H 4-34 gene segment. By ﬂowcytometric and immunohistochemical assessments, am onoclonal
CD20
þ k
þ B-lymphocyte population hasb eend emonstrated in the bone marrow of 90% of thep atients, and
lymphoplasmacytic lymphoma is af requent ﬁnding. Novel attempts at treatment for primaryC AD havem ostly been
directed against the clonal B-lymphocytes. Phase 2s tudies haves hown that therapy with the chimeric anti-CD20 antibody
rituximab produced partial response rates of more than 50% and occasional complete responses. Median response duration,
however, was only 11 months. In this review,w ed iscuss the clinical and pathogenetic features of primaryC AD,e mphasizing
the more recent data on its close association with clonal lymphoproliferative bone marrow disorders and implications for
therapy.W ea lso review the management and outline some perspectives on new therapy modalities.
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Introduction
Autoimmune hemolytic anemia (AIHA) is classiﬁed
into warma nd cold reactive antibody types. Several
entitiesa re recognized within the cold antibody group;
chronic cold agglutinin disease (CAD), acute cold
antibody mediated AIHA complicating Mycoplasma
pneumoniae or virali nfections, and paroxysmal cold
hemoglobinuria. Only CAD will be furthera ddressed
in this review.C AD has traditionally been classiﬁed
into ap rimary or idiopathic type which has been
regarded unrelated to underlying conditions, and a
secondaryt ypea ssociated with malignant disease,
most often lymphoma [1–3]. The term “cold” is
primarily derived from the immune biology of CAD,
not from the clinical features whichw ill be discussed
in detail below [4,5].
Cold hemagglutination was ﬁrst reported by Land-
steinerin1903[6]andfoundtooccurinhumanbeings
in 1918 [7]. The association of cold hemagglutination
with hemolysis was described in 1937 by Rosenthal
and Corten [8]. During the 1960s, Dacie [9]a nd
Schubothe [10] published systematic descriptions of
16CADpatientseach.Theautoantibodiesresponsible
forh emagglutinationa tl ow temperatures, cold
agglutinins (CA), mayb ef ound in the sera of healthy
subjects as well as in patientsw ith AIHA of the cold
reactive types [5,9]. CA bind to erythrocytes urface
antigens at at emperature optimumo f0 –48 C[ 4,11].
In contrast to polyclonal CA in healthy individuals,
monoclonal CA often haveah igh-thermal amplitude,
which contributes to their pathogenicity at tempera-
tures approaching3 7 8 C[ 4,11–13].
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[9,10,14] and the antigen–antibody complex induces
complement (C) activation and hemolysis [15,16].
Essential clinical manifestations of primary CAD are
hemolytic anemia andc old-induced circulatory
symptoms[ 9,10,17]. Exact estimates of the severity
of anemia andt he frequencyo fc old-induced
symptoms, however, haven ot been provided until
recenty ears[ 3,9,10,18].
Management was largely unsatisfactoryu ntil the
last decade [3,19,20]. Recently,c onsiderable progress
has been madei nt he knowledge of clinical features,
bone marrow pathology, humorala nd cellular
immunology,c andidate targets fort herapy,a nd
more efﬁcient management. We will review relevant
ﬁndingsb yo ur groupa nd others on clinical,
immunological andp athogenetic features of primary
CAD.B ased on these results, we will provide an
overview of more recentt herapeutic measures and
give somes uggestions for furthers tudies.
Epidemiologica nd clinical features
In single-center series, primaryC AD has been found
to account for1 3–15% of thec ases of AIHA
[1,21,22]. In ap opulation-basedc linical study of
primaryC AD in Norway,t he prevalence was found to
be 16 per million inhabitants and the incidence rate 1
per million inhabitants per year [3]. Little is known
aboutp ossible geographic variations. Median age of
CAD patients was 76 yearsa nd median age at onset of
symptomsw as approximately6 7y ears[ 3].T he
male/female ratio has been reported to be 0.5–0.6
whichi sn ot very different from am ale/female ratio of
0.72 in an age-matched general population. The
frequency of auto-immuned isorderso thert han CAD
does probably not differ from what is to be expectedi n
an elderly population with some female predominance
[3,4]. Median survival was about1 2.5 yearsf rom
diagnosis and median age at deathw as 82 years, which
implies al ife expectancyi nt hese patients similar to
that of an age-matched general population [3].
Cold-induced circulatorys ymptoms, although
often not emphasized by physicians, are considered
typicalf or CAD [10,17]. We found that more than
90%o fp atients with primaryC AD hads uch
symptoms, ranging from moderatea crocyanosis to
severe Raynaud phenomena precipitated even by very
slight cold exposure [3]. Although the importance of
cold exposure for exacerbation of hemolysis has been
questioned [18], characteristic seasonal variations are
fairly well documented in the literature [9,10,17,23].
According to review articles, anemiai nC AD is
variable andu sually not severe [9,17]. However, this is
deﬁnitively not always the case. Fiveo f1 6p atients
described in an early reporth ad minimum hemo-
globin (Hb) levelsb elow 7.0g/dla nd oneb elow
5.0g/dl[ 10]. In as erieso f8 6p atients, we found a
median Hb level of 8.9g/dl, and one-third of the
patientsh ad Hb levels at presentation ranging from
4.5 to 8.0g/dl. Approximately,5 0% of the patients
were considered transfusion dependenta ts ome time
during the course of the disease [3]. Paradoxically,
hemolysis is enhanced during febrile illnesses in about
two-thirds of the patients[ 3,4,24,25]. We found no
overall changeo ver time in Hb levels and parameters
of hemolysis. Hb levels decreased, however, by as
mucha s7 .7g/dl in individual patients during a
median observation time of ﬁve yearsa nd increased by
as much as 5.8g/dli no thers [3]. Thus,C AD tends to
be an on-progressive disease in most patients,
althoughﬂ uctuations in the clinical manifestations
are prevalent (Figure 1) and it shouldb ee mphasized
that there are considerable individual variations. The
ﬁgures clearly document that CAD is nota n
“indolent” disease in terms of major clinical symp-
toms and quality of life.
Immune biology
In the great majority of CAD patients, CA are speciﬁc
for the Ia ntigen, an erythrocyte surface carbohydrate
macromolecule[ 26,27]. Anti-Pra nd anti-P speciﬁ-
cities havea lso been described[ 27,28]. The concept
of CA should notb ec onfused with that of
cryoglobulin, althougho bvious similarities do exist
between primaryC AD and cryoglobulinemia type I
and II [29]. Immunoglobulins have occasionally been
described that possess both CA and cryoglobulin
properties [30,31].
Them echanismso fr ed-cella gglutination and
subsequent destruction haveb een elucidated in detail
[13,15,16,32]. Cooling of bloodd uringp assage
through acral parts of the bodya llows CA to bind to
erythrocytes and precipitate agglutination (Figure 2).
Figure 1. Exampleo fc linical course in primaryC AD.
Retrospective data from almost ten year follow-up of af emale
patient, now 74-yearso ld. Abbreviations: Chloramb, chlorambucil;
Chol, cholecystitis; Pred, prednisolone; Rit, rituximab.
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and activation via the classical pathway as shown in
Figure 3. Thus, C1 esterase activates C4 andC 2,
generating C3 convertase which leads to the formation
of C3b.U pon subsequent warming to 378 Cw hent he
blood returns to the central parts of the body, CA
detachesf romt he cell surface allowing the aggluti-
nated erythrocytes to separate from eacho ther, while
C3b remainsb ound. Some C3b-coated erythrocytes
are sequestereda nd destroyed by C3-receptor bearing
reticulo-endothelial cells, mainly in the liver.O nt he
surface of the surviving erythrocytes, C3b is cleaved
into C3c and C3d, leaving large numbers of C3d
macromolecules on the cell surface. Ca ctivation may
proceed beyond this step, resultingi nC 5a ctivation by
C3b andf ormationo ft he membrane attackc omplex
C5-9 with intravascular cell lysis. Most evidence
suggest, however,t hatt he majorm echanism of
hemolysis in stablep atientsi st he hepatic sequestra-
tion of C3b-coated erythrocytes [5,13,15,16,32].
The thermal amplitude, deﬁned as the highest
temperature at which the antibody bindst he antigen,
appearst ob em ore important than the titer with
respect to the pathogenicity of CA [12,13,33]. The
CA found in someh ealthy individuals are usually
presenti nlowtiters, and titersine xcess of 256 are very
uncommon in this group [27,34]. Furthermore, the
thermal amplitude of cold-reactive autoantibodies in
healthy subjects does note xceed1 5–208 Ca nd,
therefore, they are of no clinical signiﬁcance [27].
Christenson [35]a nd co-workersf ound in 1957
that CA may sometimes be seen as an abnormal peak
in the g -region by electrophoretic separation of serum
proteins on cellulosec olumns. Fudenberg and Kunkel
showed that these antibodies usually haveahigh (19S
or 1000kDa) molecularw eight [36]. Later, Harboe
and co-authorsf urther characterizedt he CA in CAD
as monoclonal IgMk [37–39].I narecents tudyof sera
from 172 patientsw ith monoclonal IgM associated
with av ariety of clinical disorders, CA were identiﬁed
in 10 sera (8.5%) [40].B oth, pentameric and
signiﬁcant levels of hexameric IgM have been detected
in sampleso fp uriﬁed CA from CAD patients [41].
Absence of Jc hains seems to enhance the formation of
hexamericI gM andh as been interpreteda sa
deleterious feature of IgM-mediated disorders, result-
ing in ah ighera bility to activate the Cc ascade and
therebyi nahigher lytic efﬁciencyo fI gM [41,42].
In ourp opulation-based descriptives tudy of
primaryC AD,amonoclonal band was detected by
electrophoresis and immunoﬁxation in sera from 79
(94%) of 84 patients with available data [3]. The
monoclonal immunoglobulin was of the IgM class in
71 patients( 90%), IgA and IgG in three patients
(3.5%) each,w hile two patients (2.5%) had clonal
bandso fb othI gG andI gM.T he light chain
restriction was k in 74 patients( 94%), l in two
(2.5%) and unknowni nt hree (3.5%). Since CA
detach from the erythrocytes when the blood returns
to the bodyc ore, speciﬁc direct antiglobulin test
(DAT)i su sually negative when performed with anti-
IgM. DATi sp ositive for C3d by deﬁnition (Figure 3)
[3,13,15,16]. In ourr etrospective study [3], speciﬁc
DATf or IgG was negativein 64 patients( 79% of those
with available data), while erythrocyte-bound IgG was
detected in the remaining1 7( 21%).F ivep atientswith
monoclonal IgG or biclonalI gM and IgG in serum all
displayed IgG on the erythrocyte surface. It has not
been established whether this cell-bound IgG is a
Figure 3. During passage through acral blood vessels, cooling
allows IgM cold agglutinin to bindt oe rythrocytes, causing
agglutination and binding of complement C1 complex. C1
esterase activates C4 and C2, generating C3 convertase which
binds and splits C3, leading to deposition of C3b on the erythrocyte
surface. Upon subsequent warming,I gM removes from the cell
surface and the agglutinatedc ells are detached from each other,
while C3b remains bound. C3b may in turna ctivate C5, leading to
the formation of the membrane attack complex and intravascular
cell lysis. Most destruction of C3b-coated erythrocytes, however, is
mediated by reticulo-endothelial cells in the liver [15,16,32].
Intrahepatic conversion of C3b is responsible for the deposition of
C3d on the surviving erythrocytes which are released into the
systemic circulation.
Figure 2. Blood smear from patient with primaryC AD.M ost
erythrocytes are agglutinated in variably large clumps.G iemsa, oil
immersion, objective £ 100.
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IgG type.
During maturation, each B-lymphocyte constructs
its speciﬁc immunoglobulin heavy chain by assembly
of coding sequences from the variable (VH ), diversity
(D), and joining (JH )g enes egments. The diversity
created by this recombination process is further
increased by enzymatic modiﬁcation at the cut ends
of the gene segments, followed by the event of somatic
hypermutation, typicallyo ccurring in the hypervari-
able segments of V H genes. Pascual, Thorpe,
Stevenson and others have shown that anti-I CA
found in serum samples from patientsw ithp rimary
CAD are preferentially encoded by the V H 4-34 gene
segment, formerly termed V H 4.21 [43,44]. This gene
segmenta ppearst ob eo verrepresenteda mong the
coding unitr epertoire, although it accounts for av ery
small fraction of normal circulating immunoglobulins
[43,45]. We assessed the frequencyo fV H 4-34 gene
expression by testing sera from 11 CADp atientsw ith
hemagglutinationi nhibitiona ssayu sing ther at
monoclonal anti-idiotypic antibody 9G4, which is
speciﬁc for V H 4-34 encodedp rotein. All patient sera
were conﬁrmed to be idiotope positive [4]. In contrast,
“naturally” occurring CA in healthy individuals, as
well as CA artiﬁcially induced by Rhesus (D)
immunization, areo ften derivedf rom V H gene
segments othert han V H 4-34 [45,46].
“Paradoxical” exacerbationd uring febrile
illnesses
ReducedCfactor levels in CAD were describede arly
by Jonsen [47] and others.I n1 998, Ulvestad reported
on ap atient who experienced that during the course of
the disease, the initial cold-induced exacerbations
were gradually substitutedf or “paradoxically”
enhanced hemolytic anemia during febrile episodes
[24]. The C4 levels decreased steadily ande ventually
becameu ndetectable, and the in vitro hemolytic
activity of serum( CH50) declinedt oz ero.I na
subsequent study,w ea ssessed Cp rotein levels in 15
CAD patientsa nd found reduced levels of C3 in nine
and C4 in 11 patients, six of whom hadl ow CH50 [4].
Basedo nt he records,e xacerbation of hemolysis
during acute phase reaction had occurred in ﬁve
patients. In our population-basedr etrospective study,
64% of CAD patients( 50 of 68 patientsw ith available
data on such deteriorations) reported exacerbation of
hemolytic anemiad uring febrile illnesses [3].
In order to further investigate these phenomena,
we undertookalongitudinal, prospective,
12 month follow-up study of one single patient with
“paradoxical” exacerbationso fh emolysis [25].
In the absence of any acutee vents, low C3 and
undetectableC 4l evelswere conﬁrmed. We observed a
non-functionalc lassical Cp athway and an ormal
alternativep athway.E xacerbationo fh emolytic
anemiao ccurred during pneumonia ando nce more
following ah ip fracture with subsequent surgery, and
was paralleled by increased CRP levels.D uring each
acutee vent the serum IgM levels declined tempor-
arily,a nd after the hip fracture we recorded increased
C3 levels, detectable C4, signiﬁcantly increased levels
of thep ro-inﬂammatoryc ytokinesi nterleukin-6,
tumor necrosis factor-a and interferon-g ,a nd slightly
increased interleukin-1b [25]. The most plausible
explanation for these observations is that am ajority of
CAD patientsh avel ow levels of C3 and especially C4
during steady state due to ac ontinuous consumption.
Cf actor levels, in particular low C4 levels, are rate-
limiting for hemolysis. During acutep hase reactions,
C3 and C4 levels increase due to an enhanced
production,r esultingi ne xacerbation of hemolysis.
The ﬁndings of Cc onsumptiona nd depletion may
havec linical implications. First, administration of
C-containing plasma products shouldp robably be
avoided. Second, these data explain why am ajority of
patientsw ith CAD havee xacerbations during con-
ditions associated with acutep hase reaction. Third, a
non-functionalc lassical Cp athway may affectt he
therapeutic potential of monoclonal antibodies in
CAD [48–50].
Clonal B-lymphocytes in primaryC AD
Pathogenic B-lymphocyte clones in CAD haveb een
suspected or postulatedf or decades, basedo nt he
ﬁndings of monoclonal IgMk CA in most, if not all
patients[ 3,10,31,37–39].M orer ecently,i th as
been possible to verify such cell clones directly.
Flow cytometric investigations by Silberstein and
co-workersd isclosed B-cell clones in at least some
patients[ 51]. In 1995, we reportedt he ﬁndings of
lymphoplasmacytic lymphoma in the bone marrow of
threec onsecutive patientso therwisec lassiﬁed as
having primary CAD[ 52]. In as ubsequent study by
our group, patientsw ith no clinical or radiological
evidence of an underlying lymphoma were
examined by ﬂow cytometric immunophenotyping of
bone-marrowa spirates as well as morphological
and immunohistochemical assessment of trephine
biopsies [31]. Al ymphoproliferative bone-marrow
disorder characterized by clonal CD19
þ CD20
þ k
þ
lymphocytes was detected in 10 of 11 patients.
In ar ecent retrospective study,t he medical records
of 86 patientso therwise classiﬁeda sh avingp rimary
CAD were re-examined with regard to the presence of
ac lonal lymphoproliferative bone-marrowd isorder
[3]. MonoclonalC D20
þ k
þ lymphocytes were found
in the bone marrow of most patients in whom aﬂ ow
cytometric assessment hadb een performed. Based on
previously published data [31,53], a k / l ratio . 3.5
by ﬂow cytometryw as considered strongly indicative
of ac lonall ymphoproliferativeB -celld isorder.
The median k / l ratio was 7.8 (range 0.9–186), and
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patientsw ith available data [3]. Data on bone-marrow
histology are shown in Table I. Morphologic and
immunohistochemicals igns of non-Hodgkin’sB -cell
lymphoma were found in 50 (76%) of 66 patients with
available information (Figure 4). Applying the WHO
classiﬁcation [54], 33 patientsh ad lymphoplasmacytic
lymphoma (50% of patients with available histology
data and 66% of those with ad emonstrable clonal
lymphoproliferative bone marrowd isorder).
According to recent criteria, Waldenstro ¨m’s macro-
globulinemia (WM) is deﬁned as lymphoplasmacytic
lymphoma of theb onem arrowc ombinedw ith
monoclonal IgM at any serumc oncentration [55].
Whent hese criteria were applied, 50% of CAD
patientsw ith available immunoglobulin and histology
data met the diagnostic criteria for both primary CAD
and WM [3]. On the other hand, we haveo bserved an
occasional CAD patient with monoclonal IgMk for
more than 21 yearsw ithout any demonstrable clonal
B-cell population as repeatedly assessed by ﬂow
cytometrya nd immunohistochemistry. Transform-
ation to diffuse large B-cell lymphoma appearst ob ea
rare event, occurring in 3–4% of patientswith primary
CAD after ad iseased uration of 10 years[ 3].
Cytogenetic features haveb eend ifﬁcult to assess,
probably because the cell clones usually are small and
the neoplastic cellsa re indolenta nd hardt om ake
proliferate in cultures. Trisomy 3q and translocation
8;22, respectively,h aveb eenr eported in single cases
[56,57].
CAD patientsd iagnosed by us and others to have a
low-grade lymphoproliferative bone marrow disorder
undoubtedly represent the same majority that used to
be classiﬁed as having primaryC AD [9,27,31,48].
Except in the uncommon event of transformation,
these clonal lymphoproliferative disorderss eldom, if
ever, show features of clinically overtl ymphoma even
after decades[ 3]. Furthermore, most of the rare
patients traditionally classiﬁeda sh aving secondary
CAD suffer from ar eadily demonstrable lymphoma,
often of an aggressive type, that may be associated
with IgMl as well as IgMk CA [58,59]. Therefore,w e
still thinki ti sa ppropriate to apply the termp rimary
CAD in patients not showing the classical features of
the secondaryt ype.
Diagnosis
Basedo nt he characteristics discussed in the preceding
paragraphs and available literature [1,3,5,10,17,27],
the criteria shown in Table II should be used to deﬁne
primaryC AD.T he demonstration of am onoclonal
serum immunoglobulin and ac lonal,l ymphoproli-
ferative bone-marrow disorder should notb er egarded
as an absolute prerequisite for diagnosis, since the cell
clones mayb et oo small to manifest themselves by
histopathologicﬁ ndings or be detected by ﬂow
cytometry, electrophoresis andi mmunoﬁxation.
Such veriﬁcation of clonalityd epends to al arge extent
on sensitivity and, in particular with respect to the
electrophoretic ﬁndings, on optimalp reparation and
examination of specimens.
Table II lists the diagnostic examinationst hat
shouldb ep erformed.P roblems in measurement of
bloodc ellc ounts may sometimesb ee ncountered due
to agglutination, but pre-warming of the EDTA-
bloods amples when necessaryw ill eliminate such
difﬁculties. Fors erum immunoglobulin analyses,
including cold agglutinin titration, electrophoresis,
immunoﬁxation andq uantiﬁcation of immunoglobu-
lin classes, it is essential to keep blood specimens at
378 Cf rom sampling until serum has been removed
from the clot. Assessment of thermal amplitude may
be informative, but is hardly needed for diagnostic or
therapeutic decisions. Bone-marrowe xamination by
ﬂow cytometryo fa spiratea nd careful assessment of a
trephine biopsy sample should always be performed.
Table I. Bone marrow histology in patients with primaryC AD.
n %
Normal ﬁndings or reactivel ymphocytosis 71 1
Irregular lymphoid hyperplasia 91 3
Non-Hodgkin’sBcell lymphoma 50 76
Lymphoplasmacytic lymphoma 33 50
Marginal zone lymphoma 58
Small lymphocytic lymphoma/chronic
lymphocytic leukemia
46
Clonal lymphocytosis/other small Bc ell
lymphoma
81 2
Total 66 100
Figure 4. Histopathological appearances in bone marrow trephine
biopsy from ap atient with primaryC AD.L ymphoid inﬁltrates may
be of variable size; large (A), medium-sized (B), or often small and
poorly outlined (C) which renders them barely detectable within
areas of hyperplastic erythropoiesis unless immunohistological
staining is applied( D).A –C,H E-stain;D ,A nti-CD20,
horseradish peroxidase/diaminobenzidine. All photomicrographs
are taken at identical magniﬁcation ( £ 40 objective) to enable
comparison of individuali nﬁltrates.
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According to literature, counseling on cold avoidance
shouldb et he mainstay in management of primary
CAD [17,19,60]. In 63 (73%) of 86 patients reported
by us, however, the physician and/or the patient had
notp erceived suchm easuresa ss ufﬁcient [3].
Corticosteroids anda lkylatinga gentsa re usually
ineffective [3,19,20]. Improvement following inter-
feron-a single agent therapy has been reported in a
small retrospective series,b ut in anothers eries none of
the patientsr esponded[ 61,62]. Furthermore, no
response to cladribine monotherapy was observed in a
small,p rospective study,b ut the doses of cladribine
applied in this trial were low [63]. The potential of
splenectomy hasn ot been studied systematically,b ut
theoreticalc onsiderationsa nd clinical experience
strongly discourage its use as at herapeutic procedure
[3,15,16,19,32].
The recognition of primaryC AD as ac lonal
lymphoproliferative CD20
þ B-cell disorder and the
success of treatment with the monoclonal anti-CD20
antibody rituximabi nC D20
þ non-Hodgkin’s lym-
phoma [64,65] made us ando theri nvestigators
hypothesize that rituximab therapy might also be
effective in CAD.T he adversee ffects of rituximab are
different from those of most cytotoxic drugs and less
severe [64,65], andt he B-lymphocyte elimination is
not cell cycle dependent[ 66]. One small and two
somewhatl argerp hase 2t rials [48,67,68] haveb een
published in addition to an umbero fc ase reports [69].
In the ﬁrst 16 case reports published, all patients
improveda fter rituximab therapy, andahigh
proportion of ther esponsesw erec lassiﬁed as
complete [70,71]. The explanation for such ah igh
response rate is probably that response rates estimated
from case reports are likely to be strongly inﬂuenced
by publication bias, lack of strict disease deﬁnitions,
and heterogeneous or lacking response criteria.
We reported on 37 courses of rituximab single agent
therapy administered to 27 patientsw ith primary
CAD in ap rospective,u ncontrolled trial [48]. Each
eligible patient received ac ourse of rituximab at ad ose
of 375mg/m
2 on day 1, 8, 15 and 22. Re-treatment
wasp ermitted in patients whor espondeda nd
subsequentlyr elapsed. Ther esponsec riteriaa re
summarizedi nT able III. Fourteen of 27 patients
responded to their ﬁrst course of rituximab, ands ix of
ten relapsed patientsr espondedt or e-treatment. In
both groups combined, responses were achieved after
20 of 37 courses, resultingi na no verall response rate
of 54%. We observed one completea nd 19 partial
responses. Respondersa chieved am edian increase in
Hb levelso f4 .0g/dl and am edian decrease in IgM
levels by 54%. Clinical and laboratoryd ata indicated a
beneﬁt even in somep atients classiﬁed as non-
responders. Median time to response was 1.5 months
(range,0 .5–4.0)a nd mediano bserved response
duration was 11 months (range, 2–42). No serious
adversee vents occurred. The results of as imilar trial
in 20 patients by Scho ¨llkopfa nd co-workersﬁ ti nv ery
well with our ﬁndings, althought hey reported a
Table II. Diagnosis of primaryC AD.
Comments and precautions
Criteria Chronic hemolysis
Cold agglutinin titer ^ 64 at 4 8 C
Typical DATﬁ ndings:
Polyspesiﬁc DATp ositive
Speciﬁc DATp ositivef or C3d
No malignant disease by clinical and radiological assessment
Speciﬁc DATf or IgG is usually,b ut not
always, negative
Procedures:b lood and
serum
Hemoglobin levela nd blood cell counts
Routine assessment for hemolysis
DAT. Speciﬁc DATf or C3d and IgG
Cold agglutinin (CA) titer at 4 8 C
Complement assessments (C3, C4 and CH50)
Electrophoresis with immunoﬁxation
Quantiﬁcation of IgM, IgG
and IgA
Blood specimens for CA and immunoglobulin
analyses must be kept at 378 Cf rom sampling
until serum has been removedf rom the clot
Immunoﬁxation should be performed even if no
monoclonal band is visible on electrophoresis
Procedures:b one
marrow
Trephine biopsy (including immunohistochemistry)
Flow cytometryo fa spirate
Morphology and immunohisto-chemistry of
trephine biopsies should be assessed by an
experienced hemopathologist
Radiology Chest X-ray
Abdominal ultrasonography
S. Berentsen et al. 366shorter response duration[ 68]. Some minor discre-
pancies between the results of the two studies mayb e
explained by slightly different inclusion and response
criteria.
Possible directions for future research
Theb eneﬁta chievedb yr ituximab single agent
therapy in CAD is limited by a4 5–50% failurer ate
and relatively shortr esponse duration. Furthers tudies
are warranted, therefore, in order to explain the
variable effect of rituximab therapy,i dentify possible
predictors,a nd improveo nr esponser ates and
response duration.
Even when aC D20
þ k
þ lymphocyte clone can
merely be detected and monoclonal IgM is present at
low levels, patients may haveaclinicallys evere disease
with ah igh CA titer or CA with high thermal
amplitude [4,31]. Small B-cell clones that produce
deleteriousp roteins arew ellk nown,a nd these
conditions are veryo ften difﬁcult to treat effectively
[72,73]. Thus,a ne xplanation for the difﬁculties
in achievingr emissions may be that in most cases,
small cell clones produceb iologically highly active
antibodies that must be nearly eradicated in order to
achieve clinical improvement. On the otherh and,
rituximab can induce good partial remissions even in
patientsw ho achieve only am odestd ecrease in
monoclonal IgM by about5 0% [48]. This may
indicate that reduction of the lymphocyte clone and
the concentrationo ft he auto-antibody may not be the
only pathway of therapeutic effect. In WM, the
monoclonal B-cell population can induce expansion of
circulating,p olyclonal B-lymphocytes [74]. To our
knowledge, no studiesh aveb een done to explore the
possible role of this phenomenon in CAD or any
implications for therapy.
Rituximabh as been shown to killC D20
þ cellsb ya t
least threem echanisms; C-dependent cytotoxicity
(CDC),a ntibody-directedc ellularc ytotoxicity
(ADCC), andi nductiono fa poptosis by direct
intracellular signaling [66]. Some in vitro and in vivo
data indicate that CDC is an essential mechanism of
actiona nd, therefore, the reduced availability of C
proteins in many patientsw ith CAD mayt urno ut to
be of clinical importance [49,50]. In our prospective
trial, however, we found no association between C3 or
C4 levelsa nd response to rituximab therapy [48]. The
administration of interferon-a mayr aise serum C4
levels [75] and up-regulateC D20 expression on the
surface of B-cells[ 76,77]. In ourr ituximab study,w e
intended to evaluate whether combining rituximab
and interferon-a could improveo ne fﬁcacy[ 48].
Patient or physician preferences, however, resulted in
only ﬁvepatientsr eceiving the combination,andit was
impossible to put forward any ﬁrms tatementso nt he
efﬁcacyo fc ombiningr ituximabw ith interferon-a .
Elimination of CD20
þ lymphocytes by anti-CD20
induced ADCCr equires binding of the Fc-domain of
the CD20-bound antibody to the Fc-receptor of
effector cells [66]. Polymorphism in the IgG Fcg
receptor IIIa (Fcg -RIIIa) geneh as been proposed to
inﬂuence the depletion of B-lymphocytes by rituximab
[78,79]. Although the possible consequences of such
genetic variations remain to be conﬁrmed in CAD,
clinical studies haves uggestedt hat Fcg -RIIIa poly-
morphism maye xplain the variability in the response
to rituximab therapy in WM [80].
Purine analoguesh aves hown ar emarkable efﬁcacy
in low-grade lymphoproliferative diseases, including
WM [81,82]. Although purine analogues do not seem
promising in CAD when administered as monother-
apy [63], remission has been reported in two single
casesa fter thea dministrationo fc ladribine and
ﬂudarabine, respectively [3,83]. In as mall, prospec-
tive study,c ladribinew as shown to reduce the number
of clonal cells, althoughn ot resultingi na ny signiﬁcant
clinical improvement [63]. As ynergistic effecto f
ﬂudarabine and rituximab haveb een shown in a
follicularl ymphomaB -celll ine resistant to the
cytotoxic activity of either drug alone, probably
mediated through ad own-modulationo fm embrane
CD55[ 84]. In WM,p urine analogue and rituximab
combination therapy has resulted in higher response
Table III. Response criteria used in therapeutic trials.
Complete response Absence of anemia
No signs of hemolysis
Disappearance of clinical symptomso fC AD
Undetectable monoclonal serum protein
No signs of clonal lymphoproliferation as assessed
by bone marrow histology,
immunohistochemistrya nd ﬂow cytometry
Partial response As table increase in hemoglobin levels by at
least 2.0g/dl or to the normal range
Ar eduction of serum IgM concentrationsb ya t
least 50% of the initial levelo rt ot he normal range
Improvement of clinical symptoms
Transfusion independence
No response Failure to achievec omplete or partial response
In order to qualify for any given response level,a ll criteria havet ob ef ulﬁlled
Cold agglutinin disease 367rates andm ore prolongedr emissions as comparedt o
purine analogue single agent therapy [85]. Fludar-
abine may induce AIHA, but this adversee vent seems
to occur mainly in patients with chronic lymphocytic
leukemia, and recento bservations mayi ndicate that
the additiono fr ituximabw ill reduce the risk [86].
We are now running ap hase 2s tudy on the safety
and efﬁcacyofrituximab and ﬂudarabine combination
therapy in primary CAD [87], still using the response
criteria listed in Table III. By February2 007, response
evaluation was possible in the ﬁrst nine patients,
mediana ge 72 years( range, 59–85).S ix had
previously received rituximab single-agent therapy,
resulting in one complete response and onep artial
response, while four hadb een non-responders.
Following combinationt herapy,f ourp atients
achieved ac ompleter esponse,f oura chieveda
partialr esponsea nd oned id notr espond.
Hematologic toxicity was observedi nf our patients
(grade 2, 3a nd 4, respectively)a nd infection
grade 2, nausea and dermatitis in one each. Thus,
rituximaba nd ﬂudarabine combination therapy
seems feasible even in elderly patients with CAD.
Response rates are promising and suggestive of a
higher efﬁcacy, but superiority over rituximabs ingle-
agent therapy remainst ob ep roven in an extended
study.
Since the hemolytic activity of CA is Cd ependent,
one might consider directCmodifying agents as
possible therapeutic options. Infusion of the huma-
nized, monoclonal anti-C5a ntibody eculizumab has
recently been documenteda sapowerfult herapeutic
measure in paroxysmal nocturnal hemoglobinuria
[88]. No reports haveb een published on its use in
CAD.B ased on the mechanisms of CA mediated C
activation andh emolysis discussed in the previous
paragraphs, however, ones houldt heoretically not
expectapronounced effect in stable CAD patients.
Prospectivet rialsm ay still be justiﬁedi n
refractoryp atientsw ith severe hemolysis or acute
exacerbations.
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